APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Acute Agitation and Aggression Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Acute Agitation and Aggression Drugs Market Analysis and Forecast 2026-2032

Report ID 17396022022 January 2026190 pages

Choose your research edition.

Industry ResearchAcute Agitation and Aggression Drugs Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Agitation and Aggression Drugs Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Acute Agitation and Aggression Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Agitation and Aggression Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Agitation and Aggression Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Acute Agitation and Aggression Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Acute Agitation and Aggression Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Acute Agitation and Aggression Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Acute Agitation and Aggression Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Acute Agitation and Aggression Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Acute Agitation and Aggression Drugs include Bristol-Myers Squibb, H. Lundbeck A/S, Ono Pharmaceutical, Otsuka Holdings, GlaxoSmithKline, Pfizer, Eli Lilly and Company and Johnson & Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Acute Agitation and Aggression Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Acute Agitation and Aggression Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Acute Agitation and Aggression Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acute Agitation and Aggression Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Acute Agitation and Aggression Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Acute Agitation and Aggression Drugs revenue, projected growth trends, production technology, application and end-user industry.

Acute Agitation and Aggression Drugs Segment by Company

Bristol-Myers Squibb

H. Lundbeck A/S

Ono Pharmaceutical

Otsuka Holdings

GlaxoSmithKline

Pfizer

Eli Lilly and Company

Johnson & Johnson

Acute Agitation and Aggression Drugs Segment by Type

Oral

Intramuscular Injection

Others

Acute Agitation and Aggression Drugs Segment by Application

Hospitals & Ambulatory Surgical Centers

Psychiatric Care Facilities

Others

Acute Agitation and Aggression Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Agitation and Aggression Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Agitation and Aggression Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Agitation and Aggression Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Acute Agitation and Aggression Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Acute Agitation and Aggression Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Agitation and Aggression Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acute Agitation and Aggression Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Player Table 3. Intramuscular Injection Major Player Table 4. Others Major Player Table 5. Global Acute Agitation and Aggression Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals & Ambulatory Surgical Centers Major Player Table 7. Psychiatric Care Facilities Major Player Table 8. Others Major Player Table 9. Acute Agitation and Aggression Drugs Industry Trends Table 10. Acute Agitation and Aggression Drugs Industry Drivers Table 11. Acute Agitation and Aggression Drugs Industry Opportunities and Challenges Table 12. Acute Agitation and Aggression Drugs Industry Restraints Table 13. Global Acute Agitation and Aggression Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Acute Agitation and Aggression Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Acute Agitation and Aggression Drugs Market Share by Region (2021-2026) Table 16. Global Acute Agitation and Aggression Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Acute Agitation and Aggression Drugs Market Share by Region (2027-2032) Table 18. Global Acute Agitation and Aggression Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Acute Agitation and Aggression Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Acute Agitation and Aggression Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Acute Agitation and Aggression Drugs Key Players Headquarters & Area Served Table 22. Global Acute Agitation and Aggression Drugs Players, Product Type & Application Table 23. Global Acute Agitation and Aggression Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Acute Agitation and Aggression Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Acute Agitation and Aggression Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Acute Agitation and Aggression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Acute Agitation and Aggression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Acute Agitation and Aggression Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Acute Agitation and Aggression Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Acute Agitation and Aggression Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Acute Agitation and Aggression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Acute Agitation and Aggression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Acute Agitation and Aggression Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Acute Agitation and Aggression Drugs Revenue Market Share by Application (2027-2032) Table 36. Bristol-Myers Squibb Company Information Table 37. Bristol-Myers Squibb Business Overview Table 38. Bristol-Myers Squibb Acute Agitation and Aggression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Bristol-Myers Squibb Acute Agitation and Aggression Drugs Product Portfolio Table 40. Bristol-Myers Squibb Recent Development Table 41. H. Lundbeck A/S Company Information Table 42. H. Lundbeck A/S Business Overview Table 43. H. Lundbeck A/S Acute Agitation and Aggression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. H. Lundbeck A/S Acute Agitation and Aggression Drugs Product Portfolio Table 45. H. Lundbeck A/S Recent Development Table 46. Ono Pharmaceutical Company Information Table 47. Ono Pharmaceutical Business Overview Table 48. Ono Pharmaceutical Acute Agitation and Aggression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Ono Pharmaceutical Acute Agitation and Aggression Drugs Product Portfolio Table 50. Ono Pharmaceutical Recent Development Table 51. Otsuka Holdings Company Information Table 52. Otsuka Holdings Business Overview Table 53. Otsuka Holdings Acute Agitation and Aggression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Otsuka Holdings Acute Agitation and Aggression Drugs Product Portfolio Table 55. Otsuka Holdings Recent Development Table 56. GlaxoSmithKline Company Information Table 57. GlaxoSmithKline Business Overview Table 58. GlaxoSmithKline Acute Agitation and Aggression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. GlaxoSmithKline Acute Agitation and Aggression Drugs Product Portfolio Table 60. GlaxoSmithKline Recent Development Table 61. Pfizer Company Information Table 62. Pfizer Business Overview Table 63. Pfizer Acute Agitation and Aggression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Pfizer Acute Agitation and Aggression Drugs Product Portfolio Table 65. Pfizer Recent Development Table 66. Eli Lilly and Company Company Information Table 67. Eli Lilly and Company Business Overview Table 68. Eli Lilly and Company Acute Agitation and Aggression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Eli Lilly and Company Acute Agitation and Aggression Drugs Product Portfolio Table 70. Eli Lilly and Company Recent Development Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Acute Agitation and Aggression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Johnson & Johnson Acute Agitation and Aggression Drugs Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. North America Acute Agitation and Aggression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 77. North America Acute Agitation and Aggression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 78. North America Acute Agitation and Aggression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 79. North America Acute Agitation and Aggression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 80. North America Acute Agitation and Aggression Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America Acute Agitation and Aggression Drugs Revenue by Country (2021-2026) & (US$ Million) Table 82. North America Acute Agitation and Aggression Drugs Revenue by Country (US$ Million) & (2027-2032) Table 83. Europe Acute Agitation and Aggression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 84. Europe Acute Agitation and Aggression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 85. Europe Acute Agitation and Aggression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 86. Europe Acute Agitation and Aggression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 87. Europe Acute Agitation and Aggression Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe Acute Agitation and Aggression Drugs Revenue by Country (2021-2026) & (US$ Million) Table 89. Europe Acute Agitation and Aggression Drugs Revenue by Country (US$ Million) & (2027-2032) Table 90. China Acute Agitation and Aggression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 91. China Acute Agitation and Aggression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 92. China Acute Agitation and Aggression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 93. China Acute Agitation and Aggression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia Acute Agitation and Aggression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 95. Asia Acute Agitation and Aggression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 96. Asia Acute Agitation and Aggression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 97. Asia Acute Agitation and Aggression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Acute Agitation and Aggression Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia Acute Agitation and Aggression Drugs Revenue by Region (US$ Million) & (2021-2026) Table 100. Asia Acute Agitation and Aggression Drugs Revenue by Region (US$ Million) & (2027-2032) Table 101. SAMEA Acute Agitation and Aggression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 102. SAMEA Acute Agitation and Aggression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 103. SAMEA Acute Agitation and Aggression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 104. SAMEA Acute Agitation and Aggression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 105. SAMEA Acute Agitation and Aggression Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. SAMEA Acute Agitation and Aggression Drugs Revenue by Country (2021-2026) & (US$ Million) Table 107. SAMEA Acute Agitation and Aggression Drugs Revenue by Country (US$ Million) & (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Acute Agitation and Aggression Drugs Image Figure 2. Global Acute Agitation and Aggression Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Agitation and Aggression Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Intramuscular Injection Image Figure 6. Others Image Figure 7. Global Acute Agitation and Aggression Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Acute Agitation and Aggression Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals & Ambulatory Surgical Centers Image Figure 10. Psychiatric Care Facilities Image Figure 11. Others Image Figure 12. Global Acute Agitation and Aggression Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Acute Agitation and Aggression Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Acute Agitation and Aggression Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Acute Agitation and Aggression Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Acute Agitation and Aggression Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Acute Agitation and Aggression Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Acute Agitation and Aggression Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Acute Agitation and Aggression Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Acute Agitation and Aggression Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Acute Agitation and Aggression Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Acute Agitation and Aggression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032) Figure 25. North America Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032) Figure 26. North America Acute Agitation and Aggression Drugs Revenue Share by Country (2021-2032) Figure 27. United States Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Acute Agitation and Aggression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Acute Agitation and Aggression Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Acute Agitation and Aggression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032) Figure 44. China Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Acute Agitation and Aggression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Acute Agitation and Aggression Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Acute Agitation and Aggression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Acute Agitation and Aggression Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Acute Agitation and Aggression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Intramuscular Injection
  • Others
Applications
  • Hospitals & Ambulatory Surgical Centers
  • Psychiatric Care Facilities
  • Others
Companies covered
  • Bristol-Myers Squibb
  • H. Lundbeck A/S
  • Ono Pharmaceutical
  • Otsuka Holdings
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly and Company
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Acute Agitation and Aggression Drugs Market by Type
  3. 1.2.1 Global Acute Agitation and Aggression Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Intramuscular Injection
  6. 1.2.4 Others
  7. 1.3 Acute Agitation and Aggression Drugs Market by Application
  8. 1.3.1 Global Acute Agitation and Aggression Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals & Ambulatory Surgical Centers
  10. 1.3.3 Psychiatric Care Facilities
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Acute Agitation and Aggression Drugs Market Dynamics
  1. 2.1 Acute Agitation and Aggression Drugs Industry Trends
  2. 2.2 Acute Agitation and Aggression Drugs Industry Drivers
  3. 2.3 Acute Agitation and Aggression Drugs Industry Opportunities and Challenges
  4. 2.4 Acute Agitation and Aggression Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Acute Agitation and Aggression Drugs Market Perspective (2021-2032)
  2. 3.2 Global Acute Agitation and Aggression Drugs Growth Trends by Region
  3. 3.2.1 Global Acute Agitation and Aggression Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Acute Agitation and Aggression Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Acute Agitation and Aggression Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Acute Agitation and Aggression Drugs Revenue by Players
  2. 4.1.1 Global Acute Agitation and Aggression Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Acute Agitation and Aggression Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Acute Agitation and Aggression Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Acute Agitation and Aggression Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Acute Agitation and Aggression Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Acute Agitation and Aggression Drugs Players, Product Type & Application
  8. 4.5 Global Acute Agitation and Aggression Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Acute Agitation and Aggression Drugs Market CR5 and HHI
  11. 4.6.3 2025 Acute Agitation and Aggression Drugs Tier 1, Tier 2, and Tier 3
5 Acute Agitation and Aggression Drugs Market Size by Type
  1. 5.1 Global Acute Agitation and Aggression Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Acute Agitation and Aggression Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Acute Agitation and Aggression Drugs Revenue Market Share by Type (2021-2032)
6 Acute Agitation and Aggression Drugs Market Size by Application
  1. 6.1 Global Acute Agitation and Aggression Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Acute Agitation and Aggression Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Acute Agitation and Aggression Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Acute Agitation and Aggression Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Acute Agitation and Aggression Drugs Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 H. Lundbeck A/S
  8. 7.2.1 H. Lundbeck A/S Company Information
  9. 7.2.2 H. Lundbeck A/S Business Overview
  10. 7.2.3 H. Lundbeck A/S Acute Agitation and Aggression Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 H. Lundbeck A/S Acute Agitation and Aggression Drugs Product Portfolio
  12. 7.2.5 H. Lundbeck A/S Recent Developments
  13. 7.3 Ono Pharmaceutical
  14. 7.3.1 Ono Pharmaceutical Company Information
  15. 7.3.2 Ono Pharmaceutical Business Overview
  16. 7.3.3 Ono Pharmaceutical Acute Agitation and Aggression Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Ono Pharmaceutical Acute Agitation and Aggression Drugs Product Portfolio
  18. 7.3.5 Ono Pharmaceutical Recent Developments
  19. 7.4 Otsuka Holdings
  20. 7.4.1 Otsuka Holdings Company Information
  21. 7.4.2 Otsuka Holdings Business Overview
  22. 7.4.3 Otsuka Holdings Acute Agitation and Aggression Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Otsuka Holdings Acute Agitation and Aggression Drugs Product Portfolio
  24. 7.4.5 Otsuka Holdings Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline Acute Agitation and Aggression Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Acute Agitation and Aggression Drugs Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Acute Agitation and Aggression Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Acute Agitation and Aggression Drugs Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Eli Lilly and Company
  38. 7.7.1 Eli Lilly and Company Company Information
  39. 7.7.2 Eli Lilly and Company Business Overview
  40. 7.7.3 Eli Lilly and Company Acute Agitation and Aggression Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly and Company Acute Agitation and Aggression Drugs Product Portfolio
  42. 7.7.5 Eli Lilly and Company Recent Developments
  43. 7.8 Johnson & Johnson
  44. 7.8.1 Johnson & Johnson Company Information
  45. 7.8.2 Johnson & Johnson Business Overview
  46. 7.8.3 Johnson & Johnson Acute Agitation and Aggression Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Johnson & Johnson Acute Agitation and Aggression Drugs Product Portfolio
  48. 7.8.5 Johnson & Johnson Recent Developments
8 North America
  1. 8.1 North America Acute Agitation and Aggression Drugs Revenue (2021-2032)
  2. 8.2 North America Acute Agitation and Aggression Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Acute Agitation and Aggression Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Acute Agitation and Aggression Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Acute Agitation and Aggression Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Acute Agitation and Aggression Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Acute Agitation and Aggression Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Acute Agitation and Aggression Drugs Revenue by Country
  11. 8.6.1 North America Acute Agitation and Aggression Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Acute Agitation and Aggression Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Acute Agitation and Aggression Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Acute Agitation and Aggression Drugs Revenue (2021-2032)
  2. 9.2 Europe Acute Agitation and Aggression Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Acute Agitation and Aggression Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Acute Agitation and Aggression Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Acute Agitation and Aggression Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Acute Agitation and Aggression Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Acute Agitation and Aggression Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Acute Agitation and Aggression Drugs Revenue by Country
  11. 9.6.1 Europe Acute Agitation and Aggression Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Acute Agitation and Aggression Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Acute Agitation and Aggression Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Acute Agitation and Aggression Drugs Revenue (2021-2032)
  2. 10.2 China Acute Agitation and Aggression Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Acute Agitation and Aggression Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Acute Agitation and Aggression Drugs Revenue by Type (2027-2032)
  5. 10.3 China Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Acute Agitation and Aggression Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Acute Agitation and Aggression Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Acute Agitation and Aggression Drugs Revenue by Application (2027-2032)
  9. 10.5 China Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Acute Agitation and Aggression Drugs Revenue (2021-2032)
  2. 11.2 Asia Acute Agitation and Aggression Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Acute Agitation and Aggression Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Acute Agitation and Aggression Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Acute Agitation and Aggression Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Acute Agitation and Aggression Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Acute Agitation and Aggression Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Acute Agitation and Aggression Drugs Revenue by Country
  11. 11.6.1 Asia Acute Agitation and Aggression Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Acute Agitation and Aggression Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Acute Agitation and Aggression Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Acute Agitation and Aggression Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Acute Agitation and Aggression Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Acute Agitation and Aggression Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Acute Agitation and Aggression Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Acute Agitation and Aggression Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Acute Agitation and Aggression Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Acute Agitation and Aggression Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Acute Agitation and Aggression Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Acute Agitation and Aggression Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Acute Agitation and Aggression Drugs Revenue by Country
  11. 12.6.1 SAMEA Acute Agitation and Aggression Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Acute Agitation and Aggression Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Acute Agitation and Aggression Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst